Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,374

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Ebola haemorrhagic fever

Open access
Feldmann, Heinz, Geisbert, Thomas W·2011·The Lancet
DOI 10.1016/s0140-6736(10)60667-8
Open this paper in CoChat — free account

Abstract

Ebola viruses are the causative agents of a severe form of viral haemorrhagic fever in man, designated Ebola haemorrhagic fever, and are endemic in regions of central Africa. The exception is the species Reston Ebola virus, which has not been associated with human disease and is found in the Philippines. Ebola virus constitutes an important local public health threat in Africa, with a worldwide effect through imported infections and through the fear of misuse for biological terrorism. Ebola virus is thought to also have a detrimental effect on the great ape population in Africa. Case-fatality rates of the African species in man are as high as 90%, with no prophylaxis or treatment available. Ebola virus infections are characterised by immune suppression and a systemic inflammatory response that causes impairment of the vascular, coagulation, and immune systems, leading to multiorgan failure and shock, and thus, in some ways, resembling septic shock.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(10)60667-8

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 123

  1. Kiley, 1982, Filoviridae: a taxonomic home for Marburg and Ebola viruses?, Intervirology, 18, 24, 10.1159/000149300 · DOI · Paper page
  2. Mühlberger, 1999, Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems, J Virol, 73, 2333, 10.1128/JVI.73.3.2333-2342.1999 · DOI · Paper page
  3. Basler, 2000, The Ebola virus VP35 protein functions as a type I IFN antagonist, Proc Natl Acad Sci USA, 97, 12289, 10.1073/pnas.220398297 · DOI · Paper page
  4. Noda, 2002, Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP, J Virol, 76, 4855, 10.1128/JVI.76.10.4855-4865.2002 · DOI · Paper page
  5. Sanchez, 1996, The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing, Proc Natl Acad Sci USA, 93, 3602, 10.1073/pnas.93.8.3602 · DOI · Paper page
  6. Volchkov, 1995, GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases, Virology, 214, 421, 10.1006/viro.1995.0052 · DOI · Paper page
  7. Geisbert, 2010, Prospects of immunisation against Marburg and Ebola viruses, Rev Med Virol, 10.1002/rmv.661 · DOI
  8. Siegert, 1967, [On the etiology of an unknown human infection originating from monkeys], Dtsch Med Wochenschr, 92, 2341, 10.1055/s-0028-1106144 · DOI · Paper page
  9. 1978, Ebola haemorrhagic fever in Sudan, 1976, Bull World Health Organ, 56, 247
  10. 1978, Ebola haemorrhagic fever in Zaire, 1976, Bull World Health Organ, 56, 271
  11. Cox, 1983, Evidence for two subtypes of Ebola virus based on oligonucleotide mapping of RNA, J Infect Dis, 147, 272, 10.1093/infdis/147.2.272 · DOI
  12. Le Guenno, 1995, Isolation and partial characterisation of a new strain of Ebola virus, Lancet, 345, 1271, 10.1016/S0140-6736(95)90925-7 · DOI · Paper page
  13. Towner, 2008, Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda, PLoS Pathog, 4, e1000212, 10.1371/journal.ppat.1000212 · DOI · Paper page
  14. Jahrling, 1990, Preliminary report: isolation of Ebola virus from monkeys imported to USA, Lancet, 335, 502, 10.1016/0140-6736(90)90737-P · DOI · Paper page
  15. Dalgard, 1992, Combined simian haemorrhagic fever and Ebola virus infection in Cynomolgus monkeys, Lab Anim Sci, 42, 152
  16. Miranda, 1999, Epidemiology of Ebola (subtype Reston) virus in Philippines, 1996, J Infect Dis, 179, S115, 10.1086/514314 · DOI · Paper page
  17. Barrette, 2009, Discovery of swine as a host for the Reston ebolavirus, Science, 325, 204, 10.1126/science.1172705 · DOI · Paper page
  18. Groseth, 2007, The ecology of Ebola virus, Trends Microbiol, 15, 408, 10.1016/j.tim.2007.08.001 · DOI · Paper page
  19. Monath, 1999, Ecology of Marburg and Ebola viruses: speculations and directions for future research, J Infect Dis, 179, S127, 10.1086/514281 · DOI
  20. Breman, 1999, A search for Ebola virus in animals in Democratic Republic of the Congo and Cameroon: ecologic, virologic and serologic surveys, 1979–1980, J Infect Dis, 179, S139, 10.1086/514278 · DOI
  21. Reiter, 1999, Field investigations of an outbreak of Ebola haemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies, J Infect Dis, 179, S148, 10.1086/514304 · DOI
  22. Leirs, 1999, Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflection on a vertebrate collection, J Infect Dis, 179, S155, 10.1086/514299 · DOI
  23. Morvan, 1999, Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic, Microbes Infect, 1, 1193, 10.1016/S1286-4579(99)00242-7 · DOI
  24. Swanepoel, 1996, Experimental inoculation of plants and animals with Ebola virus, Emerg Infect Dis, 2, 321, 10.3201/eid0204.960407 · DOI · Paper page
  25. Leroy, 2005, Fruit bats as reservoirs of Ebola virus, Nature, 438, 575, 10.1038/438575a · DOI · Paper page
  26. Pourrut, 2007, Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species, J Infect Dis, 196, S176, 10.1086/520541 · DOI
  27. Towner, 2009, Isolation of genetically diverse Marburg viruses from Egyptian fruit bats, PLoS Pathog, 5, e1000536, 10.1371/journal.ppat.1000536 · DOI · Paper page
  28. Leroy, 2009, Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007, Vector Borne Zoonotic Dis, 9, 723, 10.1089/vbz.2008.0167 · DOI · Paper page
  29. Gupta, 2004, Persistent infection with Ebola virus under conditions of partial immunity, J Virol, 78, 958, 10.1128/JVI.78.2.958-967.2004 · DOI · Paper page
  30. Strong, 2008, Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway, Proc Natl Acad Sci USA, 105, 17982, 10.1073/pnas.0809698105 · DOI
  31. Peters, 1999, Ebola: the virus and the disease, J Infect Dis, 179, S1
  32. Feldmann, 2007, Filoviruses: recent advances and future challenges, J Infect Dis, 196, S129, 10.1086/520550 · doi:10.1086/520550
  33. Ksiazek, 1999, ELISA for the detection of antibodies to Ebola virus, J Infect Dis, 179, S192, 10.1086/514313 · DOI · Paper page
  34. Rowe, 1999, Clinical, virologic, and immunologic follow-up of convalescent Ebola haemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo, J Infect Dis, 179, S28, 10.1086/514318 · DOI · Paper page
  35. Ryabchikova, 1996, Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis, Arch Virol, 141, 909, 10.1007/BF01718165 · DOI
  36. Bray, 1998, A mouse model for evaluation of prophylaxis and therapy of Ebola haemorrhagic fever, J Infect Dis, 178, 651, 10.1086/515386 · DOI · Paper page
  37. Connolly, 1999, Pathogenesis of experimental Ebola virus infection in guinea pigs, J Infect Dis, 179, S203, 10.1086/514305 · DOI · Paper page
  38. Bray, 2001, Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus, J Comp Pathol, 125, 243, 10.1053/jcpa.2001.0503 · DOI
  39. Geisbert, 2002, Evaluation in nonhuman primates of vaccines against Ebola virus, Emerg Infect Dis, 8, 503, 10.3201/eid0805.010284 · DOI
  40. Dowell, 1999, Transmission of Ebola haemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit, J Infect Dis, 179, S87, 10.1086/514284 · DOI · Paper page
  41. Khan, 1999, The reemergence of Ebola haemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit, J Infect Dis, 179, S76, 10.1086/514306 · DOI · Paper page
  42. Rodriguez, 1999, Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995, J Infect Dis, 179, S170, 10.1086/514291 · DOI · Paper page
  43. Zaki, 1999, A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola haemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit, J Infect Dis, 179, S36, 10.1086/514319 · DOI · Paper page
  44. Geisbert, 2003, Pathogenesis of Ebola haemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection, Am J Pathol, 163, 2347, 10.1016/S0002-9440(10)63591-2 · DOI · Paper page
  45. Jahrling, 1996, Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989–1990 U.S. epizootic, Arch Virol, 11, 115
  46. Emond, 1977, A case of Ebola virus infection, BMJ, 2, 541, 10.1136/bmj.2.6086.541 · DOI · Paper page
  47. Georges-Courbot, 1997, Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon, Emerg Infect Dis, 3, 59, 10.3201/eid0301.970107 · DOI
  48. Jaax, 1996, Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure, Arch Pathol Lab Med, 120, 140
  49. Geisbert, 2008, Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses, Vaccine, 26, 6894, 10.1016/j.vaccine.2008.09.082 · DOI · Paper page
  50. Baskerville, 1985, Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection, J Pathol, 147, 199, 10.1002/path.1711470308 · DOI
  51. Ryabchikova, 1999, An analysis of features of pathogenesis in two animal models of Ebola virus infection, J Infect Dis, 179, S199, 10.1086/514293 · doi:10.1086/514293
  52. Geisbert, 2003, Pathogenesis of Ebola haemorrhagic fever in primate models: evidence that haemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells, Am J Pathol, 163, 2371, 10.1016/S0002-9440(10)63592-4 · DOI · Paper page
  53. Zaki, 1999, Pathologic features of filovirus infections in humans, Curr Top Microbiol Immunol, 235, 97
  54. Schnittler, 1998, Marburg and Ebola haemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages?, Clin Infect Dis, 27, 404, 10.1086/517704 · doi:10.1086/517704
  55. Yang, 2000, Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury, Nat Med, 6, 886, 10.1038/78654 · DOI
  56. Baize, 1999, Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients, Nat Med, 5, 423, 10.1038/7422 · DOI · Paper page
  57. Baize, 2000, Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system?, Apoptosis, 5, 5, 10.1023/A:1009657006550 · DOI
  58. Geisbert, 2000, Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses, Lab Invest, 80, 171, 10.1038/labinvest.3780021 · DOI · Paper page
  59. Sanchez, 2004, Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels, J Virol, 78, 10370, 10.1128/JVI.78.19.10370-10377.2004 · DOI · Paper page
  60. Hensley, 2002, Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily, Immunol Lett, 80, 169, 10.1016/S0165-2478(01)00327-3 · DOI · Paper page
  61. Bosio, 2003, Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation, J Infect Dis, 188, 1630, 10.1086/379199 · DOI · Paper page
  62. Mahanty, 2003, Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses, J Immunol, 170, 2797, 10.4049/jimmunol.170.6.2797 · DOI · Paper page
  63. Baize, 2002, Inflammatory responses in Ebola virus-infected patients, Clin Exp Immunol, 128, 163, 10.1046/j.1365-2249.2002.01800.x · DOI · Paper page
  64. Yaddanapudi, 2006, Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses, FASEB J, 20, 2519, 10.1096/fj.06-6151com · DOI
  65. Volchkov, 1992, The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses, FEBS Lett, 305, 181, 10.1016/0014-5793(92)80662-Z · DOI
  66. Chepurnov, 1999, Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125-kDa GP viral protein, Immunol Lett, 68, 257, 10.1016/S0165-2478(99)00058-9 · doi:10.1016/s0165-2478(99)00058-9
  67. Villinger, 1999, Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection, J Infect Dis, 179, S188, 10.1086/514283 · DOI · Paper page
  68. Ströher, 2001, Infection and activation of monocytes by Marburg and Ebola viruses, J Virol, 75, 11025, 10.1128/JVI.75.22.11025-11033.2001 · doi:10.1128/jvi.75.22.11025-11033.2001
  69. Baize, 2002, Inflammatory responses in Ebola virus-infected patients, Clin Exp Immunol, 128, 163, 10.1046/j.1365-2249.2002.01800.x · DOI · Paper page
  70. Harcourt, 1998, Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells, Virology, 252, 179, 10.1006/viro.1998.9446 · DOI
  71. Harcourt, 1999, Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells, J Virol, 73, 3491, 10.1128/JVI.73.4.3491-3496.1999 · DOI
  72. Basler, 2003, The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3, J Virol, 77, 7945, 10.1128/JVI.77.14.7945-7956.2003 · DOI · Paper page
  73. Ebihara, 2006, Molecular determinants of Ebola virus virulence in mice, PLoS Pathog, 2, e73, 10.1371/journal.ppat.0020073 · DOI · Paper page
  74. Volchkov, 2000, Molecular characterization of guinea pig-adapted variants of Ebola virus, Virology, 277, 147, 10.1006/viro.2000.0572 · DOI
  75. Levi, 2007, Disseminated intravascular coagulation, Crit Care Med, 35, 2191, 10.1097/01.CCM.0000281468.94108.4B · DOI · Paper page
  76. Fisher-Hoch, 1985, Pathophysiology of shock and haemorrhage in a fulminating viral infection (Ebola), J Infect Dis, 152, 887, 10.1093/infdis/152.5.887 · doi:10.1093/infdis/152.5.887
  77. Fisher-Hoch, 1992, Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain, J Infect Dis, 166, 753, 10.1093/infdis/166.4.753 · doi:10.1093/infdis/166.4.753
  78. Geisbert, 2003, Mechanisms underlying coagulation abnormalities in ebola haemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event, J Infect Dis, 188, 1618, 10.1086/379724 · DOI · Paper page
  79. Elliott, 1982, Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation, J Clin Microbiol, 16, 704, 10.1128/jcm.16.4.704-708.1982 · doi:10.1128/jcm.16.4.704-708.1982
  80. Towner, 2007, High-throughput molecular detection of haemorrhagic fever virus threats with applications for outbreak settings, J Infect Dis, 196, S205, 10.1086/520601 · DOI
  81. Feldmann, 2003, Ebola virus: from discovery to vaccine, Nat Rev Immunol, 3, 677, 10.1038/nri1154 · DOI · Paper page
  82. Grolla, 2005, Laboratory diagnosis of Ebola and Marburg haemorrhagic fever, Bull Soc Pathol Exot, 98, 205
  83. Towner, 2004, Rapid diagnosis of Ebola haemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome, J Virol, 78, 4330, 10.1128/JVI.78.8.4330-4341.2004 · DOI · Paper page
  84. Lloyd, 1999, Long-term disease surveillance in Bandundu region, Democratic Republic of the Congo: a model for early detection and prevention of Ebola haemorrhagic fever, J Infect Dis, 179, S274, 10.1086/514312 · doi:10.1086/514312
  85. Smith, 2006, Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement, Biosecur Bioterror, 4, 351, 10.1089/bsp.2006.4.351 · DOI
  86. Risi, 2010, Preparing a community to care for work-related exposures to biosafety level 3 and 4 agents, Emerg Infect Dis, 16, 373, 10.3201/eid1603.091485 · doi:10.3201/eid1603.091485
  87. Huggins, 1989, Prospects for treatment of viral haemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug, Rev Infect Dis, 11, S750, 10.1093/clinids/11.Supplement_4.S750 · doi:10.1093/clinids/11.supplement_4.s750
  88. Ignatyev, 2000, Experimental study on the possibility of treatment of some haemorrhagic fevers, J Biotechnol, 83, 67, 10.1016/S0168-1656(00)00300-X · doi:10.1016/s0168-1656(00)00300-x
  89. Geisbert, 2006, Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference, J Infect Dis, 193, 1650, 10.1086/504267 · DOI · Paper page
  90. Warfield, 2006, Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers, PLoS Pathog, 2, e1, 10.1371/journal.ppat.0020001 · DOI
  91. Geisbert, 2010, Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study, Lancet, 375, 1896, 10.1016/S0140-6736(10)60357-1 · DOI · Paper page
  92. Geisbert, 2003, Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys, Lancet, 362, 1953, 10.1016/S0140-6736(03)15012-X · DOI · Paper page
  93. Hensley, 2007, Recombinant human activated protein C for the postexposure treatment of Ebola haemorrhagic fever, J Infect Dis, 196, S390, 10.1086/520598 · DOI
  94. Garbutt, 2004, Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses, J Virol, 78, 5458, 10.1128/JVI.78.10.5458-5465.2004 · DOI · Paper page
  95. Feldmann, 2007, Effective post-exposure treatment of Ebola infection, PLoS Pathog, 3, e2, 10.1371/journal.ppat.0030002 · DOI · Paper page
  96. Geisbert, 2008, Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola haemorrhagic fever in nonhuman primates, J Virol, 82, 5664, 10.1128/JVI.00456-08 · doi:10.1128/jvi.00456-08
  97. Tuffs, 2009, Experimental vaccine may have saved Hamburg scientist from Ebola fever, BMJ, 338, b1223, 10.1136/bmj.b1223 · doi:10.1136/bmj.b1223
  98. Bray, 2002, Experimental therapy of filovirus infections, Antiviral Res, 54, 1, 10.1016/S0166-3542(02)00005-0 · DOI
  99. Mupapa, 1999, Treatment of Ebola haemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee, J Infect Dis, 179, S18, 10.1086/514298 · DOI · Paper page
  100. Maruyama, 1999, Ebola virus can be effectively neutralized by antibody produced in natural human infection, J Virol, 73, 6024, 10.1128/JVI.73.7.6024-6030.1999 · DOI · Paper page
  101. Wilson, 2000, Epitopes involved in antibody-mediated protection from Ebola virus, Science, 287, 1664, 10.1126/science.287.5458.1664 · DOI · Paper page
  102. Parren, 2002, Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody, J Virol, 76, 6408, 10.1128/JVI.76.12.6408-6412.2002 · DOI · Paper page
  103. Mikhailov, 1994, The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever, Vopr Virusol, 39, 82
  104. Jahrling, 1996, Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses, Arch Virol, 11, 135
  105. Jahrling, 2007, Ebola haemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates, J Infect Dis, 196, S400, 10.1086/520587 · DOI
  106. Oswald, 2007, Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys, PLoS Pathog, 3, e9, 10.1371/journal.ppat.0030009 · DOI · Paper page
  107. Feldmann, 2005, Therapy and prophylaxis of Ebola virus infections, Curr Opin Investig Drugs, 6, 823
  108. Sullivan, 2000, Development of a preventive vaccine for Ebola virus infection in primates, Nature, 408, 605, 10.1038/35046108 · DOI · Paper page
  109. Sullivan, 2003, Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates, Nature, 424, 681, 10.1038/nature01876 · DOI · Paper page
  110. Swenson, 2008, Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections, Clin Vaccine Immunol, 15, 460, 10.1128/CVI.00431-07 · DOI
  111. Brandt, 1969, Infections in 18 000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome, Am J Epidemiol, 90, 484, 10.1093/oxfordjournals.aje.a121094 · doi:10.1093/oxfordjournals.aje.a121094
  112. Cohen, 2007, AIDS research. Did Merck's failed HIV vaccine cause harm?, Science, 318, 1048, 10.1126/science.318.5853.1048 · DOI
  113. Warfield, 2007, Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge, J Infect Dis, 196, S430, 10.1086/520583 · DOI · Paper page
  114. Halfmann, 2008, Generation of biologically contained Ebola viruses, Proc Natl Acad Sci USA, 105, 1129, 10.1073/pnas.0708057105 · DOI
  115. Halfmann, 2009, Replication-deficient ebolavirus as a vaccine candidate, J Virol, 83, 3810, 10.1128/JVI.00074-09 · DOI
  116. Bukreyev, 2006, A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge, J Virol, 80, 2267, 10.1128/JVI.80.5.2267-2279.2006 · doi:10.1128/jvi.80.5.2267-2279.2006
  117. Bukreyev, 2007, Successful topical respiratory tract immunization of primates against Ebola virus, J Virol, 81, 6379, 10.1128/JVI.00105-07 · DOI
  118. Jones, 2005, Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses, Nat Med, 11, 786, 10.1038/nm1258 · DOI · Paper page
  119. Geisbert, 2008, Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates, PLoS Pathog, 4, e1000225, 10.1371/journal.ppat.1000225 · doi:10.1371/journal.ppat.1000225
  120. Yang, 2008, A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals, Virology, 377, 255, 10.1016/j.virol.2008.04.029 · DOI
  121. Qiu, 2009, Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOV GP vaccine stimulates strong Ebola GP-specific immune responses, PLoS One, 4, e5447, 10.1371/journal.pone.0005547 · DOI
  122. Sullivan, 2009, Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule, Nat Rev Microbiol, 7, 393, 10.1038/nrmicro2129 · DOI · Paper page
  123. Geisbert, 2009, Single injection vaccine protects nonhuman primates against Marburg virus and three species of Ebola virus, J Virol, 83, 7296, 10.1128/JVI.00561-09 · DOI · Paper page

Cited by

See all 1,374

Metadata

Authors
Feldmann, H., & Geisbert, T. W.
Venue
The Lancet
Publisher
Elsevier BV
Published
2011-03
Volume
377
Issue
9768
Pages
849-862
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(10)60667-8
OpenAlex
W2102286438
Cited by
1,374
References
2
FWCI
23.25
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ebola haemorrhagic fever. https://app.cochat.ai/papers/10.1016/s0140-6736(10)60667-8
The paper
Feldmann, H., & Geisbert, T. W. (2011). Ebola haemorrhagic fever. The Lancet. https://doi.org/10.1016/s0140-6736(10)60667-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.